Quoin Pharmaceuticals develops topical drug candidates for rare genetic skin diseases, led by a lotion for Netherton Syndrome. QNRX reports earnings on Thu, Nov 5, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Prices, price targets and earnings estimates for QNRX are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plansSign in
No whale options trades in QNRX in the last 90 days.
Total alerts
0
Bullish
0
0%
Bearish
0
0%
Date span
—
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether QNRX is in one of them and how their past QNRX trades turned out.
Quoin Pharmaceuticals is a specialty drug developer based in Ashburn, Virginia. It focuses on treatments for rare and orphan diseases that have few or no approved options. Its lead product candidate, QRX003, is a topical lotion in clinical testing for Netherton Syndrome, a rare genetic skin disease, and it is also being studied for other rare skin conditions. The company plans to sell its products to patients and healthcare providers in the United States, Europe and Japan, and works with distribution partners in other countries. It has not yet commercialized any products.
